Back to Authors

Chapoval, Andrei I.

https://orcid.org/0000-0002-3426-1036

Mayo Clinic

Mayo Clinic

Citations 11

Reassessment of CD62L as a Marker of Pre‐Effector T Cells in the Tumor Draining Lymph Nodes of Head and Neck Cancer Patients
Strome, Scott E. , Flies, Dallas B. , Khurana, Dianne, Salomão, Diva R. , Tamada, Koji , Chapoval, Andrei I. , Kasperbauer, Jan L. , Olsen, Kerry D., Martin, Elizabeth A. , Chen, Lieping

Otolaryngology–Head and Neck Surgery | February 4, 2003 | Volume: 126 | Issue: 2 | Pages: 180-187

10.1067/mhn.2002.122263 Get It

OBJECTIVESCD62L was evaluated as a determinant of human pre‐effector T cells.STUDY DESIGN AND SETTINGPhenotype and cytokine secretion profiles of CD62L cells were determined based on activation status.RESULTSCD62LLow T cells demonstrated significantly higher secretion of interleukin (IL)‐10 and interferon (IFN)‐Γ than did CD62LHigh T cells. After activation, the majority of cells expressed high levels of the CD62L surface marker. Postactivation levels of IL‐10 production remained elevated or unchanged. In a murine B16 melanoma model, freshly isolated CD62LLow tumor draining lymph nodes (TDLN) T cells showed increased secretion of IL‐2 and IL‐4 but not of IL‐10 or IFN‐γ. The surface expression of CD62L and cytokine secretion patterns were maintained after activation with concomitant increases in IL‐10.CONCLUSIONOur results provide evidence that CD62LLow T cells in TDLNs of progressively growing squamous cell carcinoma of the head and neck differ phenotypically and functionally from those of mouse origin.SIGNIFICANCECharacterization of this human CD62LLow T cell population provides initial insight regarding novel surface markers in TDLN T cells that might correlate with antitumor reactivity.